• KAFM
  • Contact us
  • E-Submission
ABOUT
ARTICLE CATEGORY
BROWSE ARTICLES
AUTHOR INFORMATION

Page Path

2
results for

"Mojtaba Akhtari"

Filter

Article category

Keywords

Publication year

Authors

"Mojtaba Akhtari"

Review Article

An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians
Austin Granatowicz, Caroline I. Piatek, Elizabeth Moschiano, Ihab El-Hemaidi, Joel D. Armitage, Mojtaba Akhtari
Korean J Fam Med 2015;36(5):197-202.   Published online September 18, 2015
DOI: https://doi.org/10.4082/kjfm.2015.36.5.197

Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. Forty percent of patients with CML are asymptomatic, in whom the disease is detected solely based on laboratory abnormalities. Since the introduction of tyrosine kinase inhibitor therapy in 2001, CML has become a chronic disease for the majority of patients. Primary care physicians may be the first to recognize a new diagnosis of CML. In patients with known CML, the primary care physician may be the first to detect disease progression or adverse effects to therapy. This article provides an overview of the clinical presentation, diagnostic approach, and treatment considerations of CML.

Citations

Citations to this article as recorded by  
  • Differentiation between Chronic Myeloid Leukemia in B-Lymphoblastic Crisis and B-Cell Acute Lymphoblastic Leukemia with BCR::ABL1 Fusion Using the FISH Technique after Flow Cytometry Cell Sorting: A Case Report
    Sunghwan Lee, Yu Jeong Choi, Jin Ju Kim, Saeam Shin
    Laboratory Medicine Online.2025; 15(1): 94.     CrossRef
  • Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report
    Meng-Xiao Jia, Da-Lin Di, Zhen-Zhen Liu, Hai-Ying Wang, Lei Chen
    Experimental and Therapeutic Medicine.2025;[Epub]     CrossRef
  • Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia
    Luma Al-Ali, Raad J. Al-Ani, Maysaa M. Saleh, Alaa M. Hammad, Duaa A. Abuarqoub, Bashaer Abu-Irmaileh, Abdallah Y. Naser, Manal M. Najdawi, Manal M. Abbas, Jamal Alyoussef Alkrad
    Saudi Pharmaceutical Journal.2024; 32(2): 101931.     CrossRef
  • Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications
    Somanjana Khatua, Sudeshna Nandi, Anish Nag, Surjit Sen, Nilanjan Chakraborty, Arghya Naskar, Eda Sönmez Gürer, Daniela Calina, Krishnendu Acharya, Javad Sharifi-Rad
    European Journal of Medical Research.2024;[Epub]     CrossRef
  • Optic Neuritis in Chronic Myeloid Leukemia: A Rare Case Report in Surabaya, Indonesia
    Alvin Hartanto Kurniawan, Arifoel Hajat, Paulus Budiono Notopuro
    Research Journal of Pharmacy and Technology.2024; : 2825.     CrossRef
  • Insights into existing and futuristic treatment approach for chronic myeloid leukaemia
    Sourabh Tyagi, Anu Singh, Naveen Sharma, Rupesh Chaturvedi, Hemant Ritturaj Kushwaha
    The Indian Journal of Medical Research.2024; 159: 455.     CrossRef
  • Progesterone decreases viability and up regulates membrane progesterone receptors expression on the human Chronic Myeloid Leukemia cell line
    Vahid Bagheri, Fateme Rezaei, Razieh Alipour, Nasrin Sereshki, Vahid Ahmadipanah, Mitra Rafiee
    Cancer Genetics.2024; 288-289: 114.     CrossRef
  • Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies
    Rachel L. Mynott, Ali Habib, Oliver G. Best, Craig T. Wallington-Gates
    International Journal of Molecular Sciences.2023; 24(8): 7661.     CrossRef
  • Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
    Sunitha Shyam Sunder, Umesh C. Sharma, Saraswati Pokharel
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • Pharmacological and therapeutic potentials of cordycepin in hematological malignancies
    Zahra Taghinejad, Tohid Kazemi, Manouchehr Fadaee, Majid farshdousti hagh, Saeed Solali
    Biochemical and Biophysical Research Communications.2023; 678: 135.     CrossRef
  • A Case of JAK2V617F-Negative Myeloproliferative Neoplasm in a Young Female Presenting With Extreme Thrombocytosis
    Kelash Kumar, Assile Koubeissy, Arichanah Pulenthiran, Amrat Kumar, Amit Gulati, Brian Wolf, Stephen Peeke
    Cureus.2023;[Epub]     CrossRef
  • CD99 in malignant hematopoiesis
    Atham Ali, Vijaya Pooja Vaikari, Houda Alachkar
    Experimental Hematology.2022; 106: 40.     CrossRef
  • The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate
    Shinta Oktya Wardhani, Hani Susianti, Puji Rahayu, Yuyun Prabowowati Yueniwati, Jonny Karunia Fajar
    F1000Research.2022; 10: 1003.     CrossRef
  • Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly
    W Rajabto, YK Angkasa
    Nigerian Journal of Clinical Practice.2022; 25(3): 373.     CrossRef
  • Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
    Dan Ran Castillo, Daniel Park, Akhil Mehta, Simmer Kaur, Anthony Nguyen, Mojtaba Akhtari
    Hematology Reports.2022; 14(1): 45.     CrossRef
  • The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate
    Shinta Oktya Wardhani, Hani Susianti, Puji Rahayu, Yuyun Prabowowati Yueniwati, Jonny Karunia Fajar
    F1000Research.2022; 10: 1003.     CrossRef
  • Chronic myeloid leukaemia presenting as acute pulmonary thromboembolism
    Mallikarjuna Shetty, Rami Reddy Gari Purushotham Reddy, Srigadha Vivek Kumar, Dasarapu Sravan Kumar
    Journal of Clinical and Scientific Research.2022; 11(3): 181.     CrossRef
  • Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
    Omar Prado-Carrillo, Abner Arenas-Ramírez, Monserrat Llaguno-Munive, Rafael Jurado, Jazmin Pérez-Rojas, Eduardo Cervera-Ceballos, Patricia Garcia-Lopez
    International Journal of Molecular Sciences.2022; 23(14): 7715.     CrossRef
  • Spontaneous tumor lysis syndrome in a patient with accelerated phase chronic myeloid leukemia treated successfully with rasburicase
    Abdulrahman F. Al-Mashdali, Mohamed A. Yassin
    Medicine: Case Reports and Study Protocols.2022; 3(7): e0244.     CrossRef
  • Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience
    Avinash Kumar Singh, Mohammad Azharuddin, Narendra Agrawal, Dinesh Bhurani, Rayaz Ahmed, Manju Sharma
    SN Comprehensive Clinical Medicine.2022;[Epub]     CrossRef
  • A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia
    Rumjhum Agrawal, Joao Vieira, Jacqueline Ryan, Harish Negi, Tanvi Rajput, Regina Corbin, Ricardo Viana
    PharmacoEconomics.2022; 40(12): 1159.     CrossRef
  • A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia
    Honglan Qian, Dongxu Gang, Xiaoyu He, Songfu Jiang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation
    Sara S. I. Mohamed, Hana Mahmoud Qasim, Ahmed Mahfouz, Maab A. Osman, Ashraf O. E. Ahmed, Safa H. Al‐Azewi, Mohamad A. Yassin, Shehab Fareed
    Clinical Case Reports.2022;[Epub]     CrossRef
  • Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis
    Caleb J. Smith, Lindsey Ann Kluck, Gordon J. Ruan, Aneel A. Ashrani, Ariela L. Marshall, Rajiv K. Pruthi, Mithun Vinod Shah, Alexandra Wolanskyj-Spinner, Naseema Gangat, Mark R. Litzow, William J. Hogan, Meera Sridharan, Ronald S. Go
    The American Journal of Medicine.2021; 134(1): e31.     CrossRef
  • Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review
    Phool Iqbal, Ashraf Soliman, Vincenzo De Sanctis, Mohamed A. Yassin
    Expert Review of Hematology.2021; 14(2): 211.     CrossRef
  • Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review
    Mariana Miranda Sampaio, Maria Luísa Cordeiro Santos, Hanna Santos Marques, Vinícius Lima de Souza Gonçalves, Glauber Rocha Lima Araújo, Luana Weber Lopes, Jonathan Santos Apolonio, Camilo Santana Silva, Luana Kauany de Sá Santos, Beatriz Rocha Cuzzuol, Q
    World Journal of Clinical Oncology.2021; 12(2): 69.     CrossRef
  • Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis
    Ahmad Adel, Dina Abushanab, Anas Hamad, Mohammad Abdulla, Mohamed Izham, Mohamed Yassin
    Cancer Control.2021;[Epub]     CrossRef
  • The Levels of FoxO3a Predict the Failure of Imatinib Mesylate Therapy among Chronic Myeloid Leukemia Patients
    Shinta Oktya Wardhani, Hani Susanti, Puji Rahayu, Yuyun Yueniwati, Jonny Fajar
    Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 255.     CrossRef
  • 44-Year-Old Man With Fatigue, Weight Loss, and Leukocytosis
    Caleb J. Smith, Glenn Stewart, Kebede Begna
    Mayo Clinic Proceedings.2021; 96(7): 1944.     CrossRef
  • Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
    Hilbeen Hisham Saifullah, Claire Marie Lucas
    Cancers.2021; 13(16): 4175.     CrossRef
  • Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
    Suvankar Banerjee, Sk. Abdul Amin, Tarun Jha
    Current Chemical Biology.2021; 15(1): 19.     CrossRef
  • The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate
    Shinta Oktya Wardhani, Hani Susianti, Puji Rahayu, Yuyun Prabowowati Yueniwati, Jonny Karunia Fajar
    F1000Research.2021; 10: 1003.     CrossRef
  • High STAT5A Expression is Associated with Major Molecular Response Achievement Failure of Chronic Phase Chronic Myeloid Leukemia Patients Receiving Hydroxyurea before Imatinib: A Cross-sectional Study
    Ikhwan Rinaldi, Anastasia Putri, Melva Louisa, Sukamto Koesnoe
    Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1160.     CrossRef
  • DNA‐binding activity and cytotoxic and cell‐cycle arrest properties of some new coumarin derivatives: a multispectral and computational investigation
    Fariba Khosravifar, Gholamreza Dehghan, Seyed Kazem Bidoki, Majid Mahdavi
    Luminescence.2020; 35(1): 98.     CrossRef
  • MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers
    Omid Kooshkaki, Zohre Rezaei, Meysam Rahmati, Parviz Vahedi, Afshin Derakhshani, Oronzo Brunetti, Amir Baghbanzadeh, Behzad Mansoori, Nicola Silvestris, Behzad Baradaran
    International Journal of Molecular Sciences.2020; 21(7): 2578.     CrossRef
  • Clinical Features and Outcomes of Patients With Chronic Myeloid Leukemia Presenting With Isolated Thrombocytosis: A Systematic Review and a Case From Our Institution
    Dawood Findakly, Waqas Arslan
    Cureus.2020;[Epub]     CrossRef
  • Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study
    Andreea Varga, Ioan Tilea, Dorina Nastasia Petra, Mariana-Cornelia Tilinca, Mirela Liana Gliga, Smaranda Demian
    Journal of Clinical Medicine.2020; 9(10): 3269.     CrossRef
  • The Association Between the Level of Leukemic Stem Cells and Treatment Response Among Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate
    Shinta Oktya Wardhani, Hani Susianti, Puji Rahayu, Yuyun Yueniwati
    Clinical Cancer Drugs.2020; 7(2): 119.     CrossRef
  • Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib
    David J Hermel, Victor Chiu, Melody H Hermel, Anil Tulpule, Mojtaba Akhtari
    Journal of Oncology Pharmacy Practice.2019; 25(3): 699.     CrossRef
  • A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR–ABL1 Resistance
    Ahmed A. El Rashedy, Patrick Appiah-Kubi, Mahmoud E. S. Soliman
    The Protein Journal.2019; 38(2): 142.     CrossRef
  • The Perplexity of Synergistic Duality: Inter-molecular Mechanisms of Communication in BCR-ABL1
    Ahmed A. Elrashedy, Pritika Ramharack, Mahmoud E.S. Soliman
    Anti-Cancer Agents in Medicinal Chemistry.2019; 19(13): 1642.     CrossRef
  • Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer
    Shivtia Trop-Steinberg, Yehudit Azar
    The American Journal of the Medical Sciences.2018; 355(1): 67.     CrossRef
  • Dysregulated expression of SKP2 and its role in hematological malignancies
    Michal Kulinski, Iman W. Achkar, Mohammad Haris, Said Dermime, Ramzi M. Mohammad, Shahab Uddin
    Leukemia & Lymphoma.2018; 59(5): 1051.     CrossRef
  • Leukemia biomarker detection by using photoconductive response of CNT electrode: Analysis of sensing mechanism based on charge transfer induced Fermi level fluctuation
    Payal Gulati, Prabhjot Kaur, M.V. Rajam, Tapasya Srivastava, Md. Azahar Ali, Prabhash Mishra, S.S. Islam
    Sensors and Actuators B: Chemical.2018; 270: 45.     CrossRef
  • Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review
    Jie Fu, Yuchen Liu, Houwen Lin, Bin Wu
    Clinical Drug Investigation.2018; 38(12): 1167.     CrossRef
  • Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia
    M.P. Kawa, B. Baumert, Z. Litwińska, M. Gniot, E. Pius-Sadowska, D. Rogińska, K. Lewandowski, B. Zdziarska, B. Machaliński
    Transplantation Proceedings.2018; 50(10): 3789.     CrossRef
  • AP-1 Expression and its Clinical Relevance in Immune Disorders and Cancer
    Shivtia Trop-Steinberg, Yehudit Azar
    The American Journal of the Medical Sciences.2017; 353(5): 474.     CrossRef
  • Chronic myeloid leukaemia: A guide for practice nurses
    Margaret Ann Perry
    Practice Nursing.2017; 28(10): 419.     CrossRef
  • Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting
    Blaise Felix Faye, Nata Dieng, Moussa Seck, Macoura Gadji, Youssou Bamar Gueye, Diariatou Sy, Sokhna Aissatou Toure, Abibatou Sall, Awa Oumar Toure, Tandakha Ndiaye Dieye, Saliou Diop
    Annals of Hematology.2016; 95(10): 1603.     CrossRef
  • 9,119 View
  • 81 Download
  • 43 Web of Science
  • 49 Crossref
Review
A Primary Care Approach to Myelodysplastic Syndromes
Djamshed Samiev, Vijaya R. Bhatt, Joel D. Armitage, Lori J Maness, Mojtaba Akhtari
Korean J Fam Med 2014;35(3):111-118.   Published online May 22, 2014
DOI: https://doi.org/10.4082/kjfm.2014.35.3.111

Myelodysplastic syndromes (MDS) are probably the most common hematologic malignancies in adults over the age of 60 and are a major source of morbidity and mortality among older age groups. Diagnosis and management of this chronic blood cancer has evolved significantly in recent years and there are Food and Drug Administration-approved therapies that can extend patients' life expectancy and improve quality of life. Primary care physicians (PCPs) are often involved in the process of diagnosis and follow-up of MDS patients, especially those in low-risk groups. They can therefore play an important role in improving patient care and quality of life by ensuring early referral and participating in supportive management. There is also a shortage of oncologists which increases the importance of the role of PCPs in management of MDS patients. In the face of limited resources, PCPs can improve access and quality of care in MDS patients. This article provides an overview of the common manifestations, diagnostic approaches, and therapeutic modalities of MDS for PCPs, with a focus on when to suspect MDS, when a referral is appropriate, and how to provide appropriate supportive care for patients diagnosed with MDS.

Citations

Citations to this article as recorded by  
  • Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients
    Tamer Hellou, Guy Dumanis, Shir Portugez, Aviv Philip Goncharov, Eden Trodler, Asaf Stern, Imanuel Carlebach, Omer Kahlon, Maysan Abu Jwella, Ekram Nimer, Ahlam Athamna, Aya Berman, Gad Segal, Reut Kassif Lerner
    BMC Pharmacology and Toxicology.2025;[Epub]     CrossRef
  • Rare Case of Multiple Lineage Dysplasia Myelodysplastic Syndrome Presenting with Only Anemia: A Case Report
    Noorwati Sutandyo, Ikhwan Rinaldi, Resti Mulya Sari, Agus Susanto Kosasih, Lyana Setiawan, Kevin Winston
    Open Access Macedonian Journal of Medical Sciences.2021; 9(C): 182.     CrossRef
  • Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report
    Kelli Goo, Rosalynda Uy, Joseph Roswarski
    Journal of Oncology Pharmacy Practice.2019; 25(5): 1248.     CrossRef
  • Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols
    Pere Gascón, Andriy Krendyukov, Nicola Mathieson, Matti Aapro
    Leukemia Research.2019; 81: 35.     CrossRef
  • Managing Myelodysplastic Syndrome and the Nurse Practitioner’s Role
    Ellen Cole, Maura Abbott
    The Journal for Nurse Practitioners.2019; 15(9): 631.     CrossRef
  • 5,607 View
  • 85 Download
  • 5 Web of Science
  • 5 Crossref
TOP